Device Trial Radar · NCT06168305
Safety and Effectiveness of GENOSS® DES in Patients With Multivessel Coronary Artery Disease
Last checked: Nov 19, 2026Latest source record: Oct 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
1,000
Planned (sponsor's estimate)
Start
Nov 15, 2023
Primary completion
Feb 28, 2028
Study completion Feb 28, 2028
Sponsor
- Lead sponsor
- Genoss Co., Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 13, 2023
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 19 years
Summary
As written by the sponsor on the registry.
The investigators intend to establish a multicenter prospective observational study by enrolling and tracking patients with multivessel coronary artery disease (MVCAD) using Genoss DES, a device manufactured with pure domestic technology. The study aims to evaluate the efficacy and safety of Genoss DES in MVCAD patients.
Conditions
- Percutaneous Coronary Intervention
- Multivessel Coronary Artery Disease
Interventions
GENOSS® DES Sirolimus Eluting Coronary Stent SystemDevice
The GENOSS® DES is L-605 cobalt chromium (CoCr) platform with a strut thickness of 70µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Target Lesion Failure (TLF)Time frame: at 12 months after the procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Korea University GURO Hospital
Seoul, Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.